Q Therapeutics, Inc. Selects Goodwin Biotechnology, Inc. for Manufacturing of Its Monoclonal Antibody

SALT LAKE CITY & PLANTATION, Fla.--(BUSINESS WIRE)--Q Therapeutics, Inc. (Q) and Goodwin Biotechnology, Inc. (GBI) announced today that GBI has begun process development and will be manufacturing a monoclonal antibody used by Q in purifying its cell therapy product, Q-Cells™. This IgM antibody recognizes a unique cell surface marker that is expressed on Q-Cells (neural glial cells). On successful completion of the production, Q Therapeutics will utilize the IgM antibody to manufacture the Q-Cells in accordance with FDA requirements at a cGMP production facility. Q Therapeutics anticipates beginning Phase I trials for the treatment of transverse myelitis, a rapidly paralyzing subset of multiple sclerosis (MS), in 2009.